Skip to content

Effects of different doses of methylprednisolone on clinical outcomes in patients with severe community-acquired pneumonia

Clinical dosage investigation of methylprednisolone sodium succinate for early adjuvant therapy in patients with severe community-acquired pneumonia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045056
Enrollment
Unknown
Registered
2021-04-04
Start date
2021-06-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe community-acquired pneumonia

Interventions

Control Group:Conventional treatment without glucocorticoids
Treatment group A:On the basis of the control group, methylprednisolone sodium succinate 40 mg was injected intravenously once a day for 7 days
Treatment group B:On the basis of the control group, methylprednisolone sodium succinate 80 mg was injected intravenously once a day for 7 days
Treatment group C:On the basis of the control group, methylprednisolone sodium succinate 120 mg was injected intravenously once a day for 7 days

Sponsors

Shengli Oilfield Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Adult inpatients over 18 years old; 2.Patients met the diagnosis of SCAP, and the diagnostic criteria were implemented according to the guidelines for the diagnosis and treatment of community-acquired pneumonia for adults in China (2016 Edition) formulated by respiratory branch of Chinese Medical Association; 3.Informed consent for clinical randomized controlled trials was signed.

Exclusion criteria

Exclusion criteria: 1.Length of hospital stay <= 7 days; 2.Long-term use of glucocorticoid due to various basic diseases; 3.Allergic history or contraindications to glucocorticoid.

Design outcomes

Primary

MeasureTime frame
Oxygenation index;Mortality;

Secondary

MeasureTime frame
C-reactive protein;Interleukin-6;Procalcitonin;The rate of improvement in chest radiography;Time for body temperature to return to normal;Respiratory compliance;Airway resistance;Duration of mechanical ventilation;Duration of vasoactive drug use;ICU stay;Hospital stay;Complications;Cost in ICU;Cost in hospital;

Countries

China

Contacts

Public ContactHong Shukun

Shengli Oilfield Central Hospital

hongshukun@126.com+86 546 8779023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026